Embryonic stem cells are thought to have a significant potential for regenerative medicine. The use of nuclear transfer for the generation of """"""""customized"""""""" ES cells offers the possibility for patient-specific therapy. However, embryonic stem cell and nuclear transfer technology are highly controversial because of unresolved technical issues with human cloning and because of serious ethical objections to the use of human embryos. The key issue of the stem cell field is to accomplish reprogramming of a somatic into a pluripotent cell in the culture dish without the use of eggs. New results from our and from other laboratories demonstrate that reprogramming to pluripotency can be achieved without exposure of the somatic nucleus to the egg cytoplasm, by retrovirus-mediated transfer of Oct4, Sox2, c-myc and Klf4 into fibroblasts. The reprogrammed cells were shown to be molecularly and biologically indistinguishable from normal ES cells. This proposal has 4 aims: 1. We will define the molecular mechanism of reprogramming. 2. We will establish high throughput screens to identify small molecules that increase efficiency of reprogramming and substitute for the need to introduce any of the factors by retrovirus-mediated gene transfer. 3. Because only a small fraction of cells are converted to a pluripotent state we will define the target cells of reprogramming. Also, we will assess whether other cell types than fibroblasts can be reprogrammed. 4. The present protocols use transgenic donor cells for the selection of pluripotent cells in culture, which constitutes a major obstacle if the approach is ever to be contemplated for transplantation medicine. We will seek to establish alternative screening methods that could be used to derive reprogrammed cells from fibroblasts of non-transgenic mice. Finally, we will establish proof of principle of the therapeutic potential of reprogrammed cells in a model for Parkinson's and Sickle Cell Disease. The long-term goal of this project is to understand the molecular events that accomplish changing the epigenetic state of a somatic cell to a pluripotent state so the process can eventually be used for the treatment of patients with degenerative disease. In vitro Reprogramming of Somatic Cells into Pluripotent ES-Like Cells Public Health Relevance: The promise of embryonic stem cells in combination with nuclear transplantation is to provide patient-specific cell therapy for many degenerative diseases, but any clinical application of this approach remains highly controversial due to scientific problems and ethical objections. A potential solution to these problems is in vitro reprogramming of somatic cells to pluripotent ES cells that could be used for """"""""customized"""""""" therapy. This proposal is based on the successful in vitro generation of ES cells from fibroblasts and seeks to solve some of the key problems that need to be worked out before the approach can be considered for the potential application to medicine.

Public Health Relevance

The promise of embryonic stem cells in combination with nuclear transplantation is to provide patient-specific cell therapy for many degenerative diseases, but any clinical application of this approach remains highly controversial due to scientific problems and ethical objections. A potential solution to these problems is in vitro reprogramming of somatic cells to pluripotent ES cells that could be used for customized therapy. This proposal is based on the successful in vitro generation of ES cells from fibroblasts and seeks to solve some of the key problems that need to be worked out before the approach can be considered for the potential application to medicine.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
5R37HD045022-10
Application #
8287724
Study Section
Development - 2 Study Section (DEV2)
Program Officer
Ravindranath, Neelakanta
Project Start
2003-07-28
Project End
2013-05-31
Budget Start
2012-05-01
Budget End
2013-05-31
Support Year
10
Fiscal Year
2012
Total Cost
$768,246
Indirect Cost
$374,273
Name
Whitehead Institute for Biomedical Research
Department
Type
DUNS #
120989983
City
Cambridge
State
MA
Country
United States
Zip Code
02142
Wiehle, Laura; Raddatz, Günter; Musch, Tanja et al. (2016) Tet1 and Tet2 Protect DNA Methylation Canyons against Hypermethylation. Mol Cell Biol 36:452-61
Stelzer, Yonatan; Wu, Hao; Song, Yuelin et al. (2016) Parent-of-Origin DNA Methylation Dynamics during Mouse Development. Cell Rep 16:3167-80
Liu, X Shawn; Wu, Hao; Ji, Xiong et al. (2016) Editing DNA Methylation in the Mammalian Genome. Cell 167:233-247.e17
Banerjee, Abhishek; Rikhye, Rajeev V; Breton-Provencher, Vincent et al. (2016) Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome. Proc Natl Acad Sci U S A 113:E7287-E7296
Muffat, Julien; Li, Yun; Yuan, Bingbing et al. (2016) Efficient derivation of microglia-like cells from human pluripotent stem cells. Nat Med 22:1358-1367
Ji, Xiong; Dadon, Daniel B; Powell, Benjamin E et al. (2016) 3D Chromosome Regulatory Landscape of Human Pluripotent Cells. Cell Stem Cell 18:262-75
Stelzer, Yonatan; Jaenisch, Rudolf (2015) Monitoring Dynamics of DNA Methylation at Single-Cell Resolution during Development and Disease. Cold Spring Harb Symp Quant Biol :
Cimmino, Luisa; Dawlaty, Meelad M; Ndiaye-Lobry, Delphine et al. (2015) TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol 16:653-62
Zhao, Zhigang; Chen, Li; Dawlaty, Meelad M et al. (2015) Combined Loss of Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in Mice. Cell Rep 13:1692-704
Stelzer, Yonatan; Shivalila, Chikdu Shakti; Soldner, Frank et al. (2015) Tracing dynamic changes of DNA methylation at single-cell resolution. Cell 163:218-29

Showing the most recent 10 out of 67 publications